|
BRCC3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.40310000285027E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.12399999974144E-07 |
| Normal-vs-Stage2 |
3.841600E-03 |
| Normal-vs-Stage3 |
7.93009999888739E-08 |
| Normal-vs-Stage4 |
3.90500000002625E-07 |
| Stage1-vs-Stage2 |
1.871200E-01 |
| Stage1-vs-Stage3 |
2.459200E-01 |
| Stage1-vs-Stage4 |
2.732800E-01 |
| Stage2-vs-Stage3 |
5.504000E-02 |
| Stage2-vs-Stage4 |
5.382100E-02 |
| Stage3-vs-Stage4 |
8.600400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.11949999773253E-08 |
| Normal-vs-AfricanAmerican |
7.362200E-04 |
| Normal-vs-Asian |
4.30669999995636E-06 |
| Caucasian-vs-AfricanAmerican |
9.536400E-01 |
| Caucasian-vs-Asian |
8.262200E-01 |
| AfricanAmerican-vs-Asian |
8.370600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.84820000309816E-08 |
| Normal-vs-Female |
9.43090000538049E-08 |
| Male-vs-Female |
3.284400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.25069999982131E-07 |
| Normal-vs-Age(41-60Yrs) |
7.47699999692486E-08 |
| Normal-vs-Age(61-80Yrs) |
4.01969999996865E-06 |
| Normal-vs-Age(81-100Yrs) |
8.953800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.084000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.654000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.675600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.143800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.105400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.636400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.814600E-01 |
| Classical-VS-Follicular |
9.474800E-01 |
| Classical-VS-Other |
2.734400E-01 |
| Classical-VS-Normal |
2.57509999990191E-07 |
| Tall-VS-Follicular |
4.177200E-01 |
| Tall-VS-Other |
4.804800E-01 |
| Tall-VS-Normal |
4.27160000000537E-05 |
| Follicular-VS-Other |
3.571200E-01 |
| Follicular-VS-Normal |
8.40830000000681E-05 |
| Other-VS-Normal |
4.237200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.15449999957573E-07 |
| Normal-vs-N1 |
1.55089999953617E-07 |
| N0-vs-N1 |
1.002200E-01 |
|
|
